Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | TEK | Q02763 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 6/20 | 0.40 |
| ▸ | MTOR | P42345 | 4/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572624 | 0.91 | PIK3CA (0.40) | TEKNAMPTMTORSCN2ASCN10A | |
| SCHEMBL3578235 | 0.86 | SCN2A (0.45) | LCKTEKNAMPTSCN2ASCN10A | |
| SCHEMBL3580192 | 0.84 | LCK (0.43) | LCKTEKNAMPTMTORHTT | |
| SCHEMBL3582225 | 0.79 | EGFR (0.54) | LMNA | |
| SCHEMBL3575251 | 0.79 | SCN2A (0.49) | NAMPTSCN2ASCN10APIK3CA | |
| SCHEMBL3576468 | 0.77 | TEK (0.49) | LCKTEKNAMPTSCN2ASCN10A | |
| SCHEMBL27716221 | 0.77 | AURKA (0.37) | LCKTEKMTORPIK3CAPIK3R1 | |
| SCHEMBL3582962 | 0.76 | BTK (0.43) | TEKNAMPTSCN2ASCN10AKDR | |
| SCHEMBL3583017 | 0.76 | LCK (0.44) | LCKTEKKDR | |
| SCHEMBL3584195 | 0.76 | CNR2 (0.49) | LCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | LCK 326/4885TEK 1/4885NAMPT 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.